The global Omics-Based Clinical Trials Market size was valued at USD 28.5 billion in 2023, and the market is projected to reach USD 45.5 billion by the end of 2030, with growth at a CAGR of 6.9% during the forecast report 2023-2030.
Increasing Adoption of Next-Generation Sequencing (NGS): NGS is a powerful technology that enables the sequencing of large amounts of DNA or RNA in a relatively short period of time. NGS is being used in the design and conduct of clinical trials to identify patient subpopulations that are more likely to respond to a given therapy, as well as to monitor disease progression and treatment response.
Growing Importance of Biomarkers: Biomarkers are measurable indicators of disease or treatment response. Omics-based technologies are being used to identify and validate biomarkers that can be used to guide the development of personalized therapies and monitor treatment response.
Real-world data are those that are gathered outside of clinical trials, such as data from insurance claims and electronic health records. Omics-based technologies are being used to analyses actual data in order to pinpoint patient subpopulations that can profit from a certain therapy and to track treatment effectiveness in a practical scenario.
Collaboration and Partnerships: To plan and carry out clinical trials that use omics-based technologies, pharmaceutical corporations, academic institutions, and governmental organizations collaborate heavily in the market for omics-based clinical trials. The development of more focused and effective clinical studies, as well as the exchange of information and resources, are made possible through these collaborations.
The phrase "omics-based clinical trials market" refers to the use of omics technologies like genomics, proteomics, and metabolomics when talking about the planning and implementation of clinical trials. Omics-based clinical trials are designed to further the development of customized medicine, provide a deeper understanding of illness causes, and pinpoint patient subpopulations more likely to respond to a certain treatment.
Some of the factors propelling the market for omics-based clinical trials include the need for personalized medicine, the development of omics technology, and a trend toward more targeted and efficient clinical trials. Clinical trials based on omics are being used to study a wide range of diseases, including cancer, cardiovascular disease, neurological disorders, and rare diseases.
Technological Development: The growth of omics technologies including genomics, proteomics, and metabolomics is one of the key factors driving the market expansion for clinical trials based on omics data. To give a more precise and detailed understanding of disease processes, patient subpopulations, and therapy responses, new technologies are being created. The growing application of omics-based technologies in clinical trials has enabled the creation of personalized therapies and more effective trial designs.
Regulatory Frameworks: A number of governmental organizations and entities oversee the omics-based clinical trial sector. The general morality and safety of clinical research, as well as their accessibility and financial viability, may be impacted by these restrictions.
Need for Personalized Medicine: The use of omics-based technologies in clinical trials is being fueled by the rising need for personalized medicine. Omics-based technologies enable the creation of more specialized and effective treatments by giving more thorough knowledge of disease processes and patient subpopulations.
Collaborations and Partnerships: For the design and execution of omics-based clinical trials, the collaboration between industry players—including pharmaceutical and biotech firms, clinical research organizations, and academic institutions—is crucial. Collaborations allow for the exchange of information and resources as well as the creation of more effective and focused trial designs.
The management and analysis of enormous volumes of data produced by omics-based technology can be difficult. Businesses in the sector need to spend money on data management and analysis.
As per the report, the global Omics-Based Clinical Trials Market is segmented into Type, Application, and Regions. The report covers detailed information on market size, Share, Growth, Value, Volume Analysis, Demand analysis, new market entry, competition insights, market drivers, challenges, opportunities, and Restraints. Further, company profile analysis, company revenue, Strategies, Sales, company acquisition, partnership, mergers, latest trends in the industry, regional and country-level insights, and competitive intelligence data is provided in the research report.
Further, the global market is geographically divided into major regions, and countries including North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. Further, major countries focused in the global study report: United States, Canada, United Kingdom, Spain, Germany, Italy, France, Mexico, Russia, Ukraine, China, Japan, South Korea, India, Singapore, Malaysia, Australia, Qatar, Kingdom of Saudi Arabia, South Africa, Brazil, Argentina, and other countries are covered in the research study.
By Phase
• Phase I
• Phase II
• Phase III
• Phase IV
By Study Type
• Interventional
• Observational
• Expanded Access Studies
By Application
• Oncology
• Cardiology
• Respiratory Diseases
• Skin Diseases
• CNS Disorders
• Immunology
• Genetic Diseases
• Others
Geographical Classification Analysis:
- North America
- Latin America
- Europe
- Middle East and Africa
- Asia Pacific
Regional Insights:
• North American market to remain in control over the global market during 2022-2030. In the North American region, the United States occupied the highest share of the market in this region, and the US country is projected to follow the same trend over the forecast time 2022-2030, followed by Canada.
• Europe holds the second largest share producer in the global Disposable Medical Sensors Market during the forecast period 2022-2030. Asia Pacific region is expected to be registered as the fastest-growing market in the global market by 2030.
• Most developing countries in Asia Pacific remain the focus of leading Disposable Medical Sensors companies, with a large portion of these companies investing in new entry and business expansion strategies
• The market in the Middle East and Africa is projected to show prominent growth opportunities in the coming years from 2023-2030. Due to the rising focus from the government of the Middle East and African countries on emerging healthcare infrastructure manufacturing and distribution are mostly contributing to the global market in the MEA region.
• The Latin American Disposable Medical Sensors Market registered a substantial share of the global market in 2022, and it is projected to remain its presence in the market.
• Parexel International Corporation
• Pharmaceutical Product Development, LLC
• Charles River Laboratories Inc.
• ICON plc
• SGS SA
• Eli Lilly and Company
• Pfizer Inc.
• Covance Inc.
• Novo Nordisk A/S
• Rebus Bio
1. Executive Summary
1.1 Introduction to Omics-Based Clinical Trials Markets
1.2 Omics-Based Clinical Trials Market Size Outlook, 2021- 2030
1.3 Growth Opportunities in Omics-Based Clinical Trials Industry
1.4 Winning Strategies for the post-pandemic future
2. Report Guide
2.1 Market Definition and Scope
2.2 Market Segmentation
2.3 Research Methodology
2.4 Forecast Methodology
2.5 List of Abbreviations
3. Growth Opportunity Analysis
3.1 Key Omics-Based Clinical Trials Market Trends
3.2 Key Omics-Based Clinical Trials Market Growth Drivers
3.3 Key Omics-Based Clinical Trials Market Growth Restraints
4 Omics-Based Clinical Trials Market Outlook – Scenario Analysis
4.1 Low Growth Case Scenario Forecasts
4.2 Reference Growth Case Scenario Forecasts
4.3 High Growth Case Scenario Forecasts
5. Omics-Based Clinical Trials Market Segmentation- Outlook by Phase
5.1 Phase I Market Outlook to 2030
5.2 Phase II Market Outlook to 2030
5.3 Phase III Market Outlook to 2030
5.4 Phase IV Market Outlook to 2030
6. Omics-Based Clinical Trials Market Segmentation- Outlook by Study Type
6.1 Interventional Market Outlook to 2030
6.2 Observational Market Outlook to 2030
6.3 Expanded Access Studies Market Outlook to 2030
7. Omics-Based Clinical Trials Market Segmentation- Outlook by Application
7.1 Oncology Market Outlook to 2030
7.2 Cardiology Market Outlook to 2030
7.3 Respiratory Diseases Market Outlook to 2030
7.4 Skin Diseases Market Outlook to 2030
7.5 CNS Disorders Market Outlook to 2030
7.6 Immunology Market Outlook to 2030
7.7 Genetic Diseases Market Outlook to 2030
7.8 Others Market Outlook to 2030
8. North America Omics-Based Clinical Trials Market Outlook and Opportunities to 2030
8.1 Market Snapshot, 2023
8.2 North America Omics-Based Clinical Trials Market Growth Opportunities
8.3 North America Omics-Based Clinical Trials Market Outlook by Application
8.4 North America Omics-Based Clinical Trials Market Outlook by Type
8.5 North America Omics-Based Clinical Trials Market Outlook by Country
8.6 United States Omics-Based Clinical Trials Market Outlook
8.7 Canada Omics-Based Clinical Trials Market Outlook
8.8 Mexico Omics-Based Clinical Trials Market Outlook
9. Europe Omics-Based Clinical Trials Market Outlook and Opportunities to 2030
9.1 Market Snapshot, 2023
9.2 Europe Omics-Based Clinical Trials Market Outlook by Application
9.3 Europe Omics-Based Clinical Trials Market Outlook by Type
9.4 Europe Omics-Based Clinical Trials Market Outlook by Country
9.5 Germany Omics-Based Clinical Trials Market Outlook
9.6 France Omics-Based Clinical Trials Market Outlook
9.7 United Kingdom Omics-Based Clinical Trials Market Outlook
9.8 Spain Omics-Based Clinical Trials Market Outlook
9.9 Italy Omics-Based Clinical Trials Market Outlook
9.10 Other Europe Omics-Based Clinical Trials Market Outlook
10. Asia Pacific Omics-Based Clinical Trials Market Outlook and Opportunities to 2030
10.1 Market Snapshot, 2023
10.2 Asia Pacific Omics-Based Clinical Trials Market Outlook by Application
10.3 Asia Pacific Omics-Based Clinical Trials Market Outlook by Type
10.4 Asia Pacific Omics-Based Clinical Trials Market Outlook by Country
10.5 China Omics-Based Clinical Trials Market Outlook
10.6 Japan Omics-Based Clinical Trials Market Outlook
10.7 India Omics-Based Clinical Trials Market Outlook
10.8 Other Asia Pacific Omics-Based Clinical Trials Market Outlook
11. Latin America Omics-Based Clinical Trials Market Outlook and Opportunities to 2030
11.1 Market Snapshot, 2023
11.2 Latin America Omics-Based Clinical Trials Market Outlook by Application
11.3 Latin America Omics-Based Clinical Trials Market Outlook by Type
11.4 Latin America Omics-Based Clinical Trials Market Outlook by Country
11.5 Brazil Omics-Based Clinical Trials Market Outlook
11.6 Argentina Omics-Based Clinical Trials Market Outlook
11.7 Other Latin America Omics-Based Clinical Trials Market Outlook
12. Middle East and Africa Omics-Based Clinical Trials Market Outlook and Opportunities to 2030
12.1 Market Snapshot, 2023
12.2 Middle East and AfricaOmics-Based Clinical Trials Market Outlook by Application
12.3 Middle East and AfricaOmics-Based Clinical Trials Market Outlook by Type
12.4 Middle East and AfricaOmics-Based Clinical Trials Market Outlook by Country
12.5 Saudi Arabia Omics-Based Clinical Trials Market Outlook
12.6 UAE Omics-Based Clinical Trials Market Outlook
12.7 South Africa Omics-Based Clinical Trials Market Outlook
12.8 Other Middle East and Africa Omics-Based Clinical Trials Market Outlook
13 Profiles of major Omics-Based Clinical Trials Companies
Parexel International Corporation
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
Pharmaceutical Product Development, LLC
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
Charles River Laboratories Inc.
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
ICON plc
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
SGS SA
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
Eli Lilly and Company
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
Pfizer Inc.
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
Covance Inc.
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
Novo Nordisk A/S
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
Rebus Bio
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
14. Appendix
14.1 Publisher’s Expertise
14.2 List of Tables and Charts
14.3 List of Exhibits
14.4 Legal Disclaimer
By Phase
• Phase I
• Phase II
• Phase III
• Phase IV
By Study Type
• Interventional
• Observational
• Expanded Access Studies
By Application
• Oncology
• Cardiology
• Respiratory Diseases
• Skin Diseases
• CNS Disorders
• Immunology
• Genetic Diseases
• Others